Literature DB >> 10097901

Crucial points at diagnosis. Type 2 diabetes or slow type 1 diabetes.

P Zimmet1, R Turner, D McCarty, M Rowley, I Mackay.   

Abstract

Two major types of diabetes have been recognized since the late 1930s. However, in recent times there have been major changes in classification and understanding of these types, including improved knowledge of maturity-onset diabetes in the young, with the identification of mutations relating to impaired insulin secretion and the recognition of slow-onset type 1 diabetes in adults now designated as latent autoimmune diabetes in adults (LADA). A major problem area in diabetes classification concerns cases of slowly progressive forms of type 1 and type 2 diabetes, particularly in adults aged 25-50 years. This is a more contemporary problem because cases of type 2 diabetes are presenting at an increasingly younger age. In the landmark U.K. Prospective Diabetes Study of type 2 diabetes, islet cell antibodies (ICAs) and antibodies to glutamic acid decarboxylase (anti-GAD) were measured at diagnosis in 3,672 patients. The overall proportion with ICAs was 6%, and anti-GADs was 10%. These subjects clearly had type 1 diabetes or LADA by both phenotypic and genotypic features. The presence of auto antibodies correlated particularly with a younger age and phenotypic features consistent with type 1 diabetes (e.g., early age at diagnosis, lower BMI, and reduced beta-cell function). Overall, of patients requiring insulin by 6 years, 38% were anti-GAD+ at baseline compared with 5.3% of those not on insulin at 6 years. Antibodies to GAD indicate an underlying autoimmune process and have a high positive predictive value for type 1 diabetes and future insulin dependency in adults.

Entities:  

Mesh:

Year:  1999        PMID: 10097901

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  23 in total

1.  [LADA-type diabetes. A category to be taken into account in primary health care].

Authors:  M Ferré; A Donado; M T García; B Costa
Journal:  Aten Primaria       Date:  2003-01       Impact factor: 1.137

Review 2.  Metabolic surgery for the treatment of type 2 diabetes in patients with BMI <35 kg/m2: an integrative review of early studies.

Authors:  M Fried; G Ribaric; J N Buchwald; S Svacina; K Dolezalova; N Scopinaro
Journal:  Obes Surg       Date:  2010-06       Impact factor: 4.129

Review 3.  The role of the immune system in the insulin resistance syndrome.

Authors:  Michael R Lewis; Russell P Tracy
Journal:  Curr Diab Rep       Date:  2002-02       Impact factor: 4.810

4.  Surgery for diabetes at lower BMI: some caution.

Authors:  Mervyn Deitel
Journal:  Obes Surg       Date:  2008-08-30       Impact factor: 4.129

5.  Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus.

Authors:  David B Sacks; Mark Arnold; George L Bakris; David E Bruns; Andrea Rita Horvath; M Sue Kirkman; Ake Lernmark; Boyd E Metzger; David M Nathan
Journal:  Diabetes Care       Date:  2011-06       Impact factor: 19.112

6.  C-peptide predicts the remission of type 2 diabetes after bariatric surgery.

Authors:  Wei-Jei Lee; Keong Chong; Kong-Han Ser; Jung-Chien Chen; Yi-Chih Lee; Shu-Chun Chen; Yen-How Su; Min-Han Tsai
Journal:  Obes Surg       Date:  2012-02       Impact factor: 4.129

7.  Autoimmune polyglandular syndrome type 3 complicated by mineralocorticoid-responsive hyponatremia of the elderly.

Authors:  Hidekatsu Yanai; Seiko Okamoto; Junwa Kunimatsu
Journal:  World J Diabetes       Date:  2010-09-15

8.  Deciphering normal blood gene expression variation--The NOWAC postgenome study.

Authors:  Vanessa Dumeaux; Karina S Olsen; Gregory Nuel; Ruth H Paulssen; Anne-Lise Børresen-Dale; Eiliv Lund
Journal:  PLoS Genet       Date:  2010-03-12       Impact factor: 5.917

Review 9.  Anti-CD38 autoantibodies in type? diabetes.

Authors:  Roberto Mallone; Paolo Cavallo Perin
Journal:  Diabetes Metab Res Rev       Date:  2006 Jul-Aug       Impact factor: 4.876

10.  Glutamic acid decarboxylase antibodies are indicators of the course, but not of the onset, of diabetes in middle-aged adults: the Atherosclerosis Risk in Communities Study.

Authors:  A Vigo; B B Duncan; M I Schmidt; D Couper; G Heiss; J S Pankow; C M Ballantyne
Journal:  Braz J Med Biol Res       Date:  2007-07       Impact factor: 2.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.